Modern Architect · 1954 — Present

Jeremy Levin

Biotech visionary pioneering neuroscience drug development after transforming a generics giant.

Country

South Africa

Continent

Africa

Industry

Biotechnology

Role

CEO, Entrepreneur

Jeremy Levin is a physician and biotech executive, recognized for his transformative tenure as CEO of Teva Pharmaceutical Industries and his subsequent leadership in neurological drug development. He currently helms Ovid Therapeutics, focused on rare neurological disorders.

Biography

Jeremy Levin's career trajectory exemplifies a strategic shift from large-cap pharmaceutical leadership to specialized biotech innovation. His tenure as President and CEO of Teva Pharmaceutical Industries from 2012 to 2014 was marked by a strategic pivot away from an over-reliance on generics towards a renewed focus on innovative specialty products, particularly in CNS and respiratory. This involved divesting non-core assets and restructuring R&D, a difficult but necessary move to reposition a global leader. Prior to Teva, Levin held significant roles at Bristol-Myers Squibb, where he led the company’s efforts in oncology, neuroscience, and virology, and at Novartis, overseeing its neuroscience and gastrointestinal franchises. These experiences provided a deep operational understanding of global pharmaceutical R&D, commercialization, and strategic portfolio management across diverse therapeutic areas. His leadership at Teva showcased the complexities of managing a multi-national pharmaceutical entity under immense competitive and financial pressures. Following his departure from Teva, Levin transitioned into an entrepreneurial role, co-founding Ovid Therapeutics in 2014. This move signals a deliberate, focused approach to address unmet medical needs within neurological disorders, particularly rare pediatric epilepsies. This transition from a C-suite role at a ~40,000-employee company to building a lean biotech startup from inception highlights a willingness to operate across different scales and risk profiles. At Ovid Therapeutics, Levin has successfully raised significant capital, including a Series A of $39 million in 2015 and an IPO on NASDAQ in 2017 (OVSD, now OVID), demonstrating his ability to attract investment in highly specialized and high-risk therapeutic areas. The company's focus on developing treatments for conditions like Angelman syndrome and Fragile X syndrome, leveraging partnerships with larger pharmaceutical companies like Takeda, underscores a strategic approach to risk mitigation and product development in challenging orphan drug markets. His career journey provides insights into managing corporate transitions, re-prioritizing R&D, executing M&A, and building value in both mature and nascent pharmaceutical sectors. It also exemplifies how experienced leadership can translate across different organizational structures, from global pharmaceutical giants to specialized biopharmaceutical startups, with a consistent focus on innovation and patient impact.

Accomplishments

01Served as President and CEO of Teva Pharmaceutical Industries (2012-2014), implementing a major strategic overhaul toward specialty pharmaceuticals.
02Co-founded and currently leads Ovid Therapeutics (2014-present), securing substantial capital and public listing (NASDAQ: OVID) for neurological drug development.
03Held executive roles at Bristol-Myers Squibb, leading oncology, neuroscience, and virology portfolios.
04Led global business development and licensing at Novartis, overseeing neuroscience and gastrointestinal franchises.
05Successfully executed partnerships and licensing deals at Ovid, including a significant collaboration with Takeda Pharmaceutical Company.
06Guided Ovid Therapeutics' clinical pipeline development for rare neurological disorders, such as Angelman syndrome and Fragile X syndrome.
07Oversaw the divestiture of non-core assets at Teva, streamlining the company's focus on its core innovative strengths.
08Instrumental in shifting Teva's R&D focus from general generics to complex generics and specialty medicines.

Lessons for Operators

Strategic leadership requires active portfolio re-evaluation and willingness to divest non-core assets.

Focusing on high-value, specialized markets can generate substantial returns even with fewer products.

Leveraging partnerships with larger pharma companies is critical for de-risking and accelerating development in biotech.

Founding and scaling a biotech requires distinct skills from leading a global pharma, emphasizing capital efficiency and targeted R&D.

Effective R&D restructuring demands painful short-term decisions to secure long-term innovation and profitability.

Identifying and addressing unmet medical needs in rare diseases can attract significant investment and clinical potential.

Successful capital allocation shifts from late-stage market dominance to early-stage scientific validation during career transitions.

The Operator's Playbook

Key Takeaways

Practical lessons distilled for operators, investors, C-levels, and capital allocators.

Lesson 01

Portfolio Refocusing

For C-levels and fund managers, Levin's Teva tenure demonstrates that divesting underperforming or non-strategic assets, even if culturally difficult, is crucial for improving capital efficiency and concentrating resources on high-potential segments, thereby enhancing long-term shareholder value. Conduct regular, rigorous portfolio reviews that challenge existing asset allocations.

Lesson 02

Specialization Pays

Operators and investors should recognize that deep specialization in niche, high-need therapeutic areas (e.g., rare neurological disorders at Ovid) can create significant value. This strategy mitigates broad market competition and allows for premium pricing and strong intellectual property protection, leading to higher ROI on R&D expenditure.

Lesson 03

Strategic Alliances

Fund managers and enterprise leaders need to prioritize and execute strategic partnerships, as exemplified by Ovid's collaboration with Takeda. These alliances provide crucial non-dilutive capital, access to commercial infrastructure, and external validation, significantly de-risking early-stage drug development and maximizing return on investment for small biotechs.

Lesson 04

Evolve Leadership Skills

For C-levels and aspiring entrepreneurs, Levin's transition from leading a multi-billion dollar corporation to founding a lean startup shows the importance of adapting leadership styles and operational frameworks. Success demands different skill sets—from managing global complexities to driving capital-efficient innovation—emphasizing flexibility and continuous learning.

Lesson 05

R&D Prioritization

Operators should continually scrutinize and restructure R&D budgets to align with strategic goals, even if unpopular. Levin's reorientation of Teva's R&D towards specialty drugs, rather than generic volume, underscores that innovation-driven growth requires a disciplined reallocation of resources to projects with the highest scientific and commercial potential.

Mental Models

Frameworks & Principles

Named frameworks and strategic principles they popularized or embodied.

Strategic Portfolio Rationalization

A framework for divesting non-core or underperforming assets to focus capital and resources on strategic, high-growth areas, enhancing overall corporate value.

When to useWhen a company's portfolio has become diversified or includes assets that no longer align with its core mission or future growth strategy, leading to diluted resources and unfocused efforts.

Focused Innovation through Specialization

A model emphasizing the development of deep expertise and targeted product pipelines within niche, high-value markets, particularly in pharmaceuticals where unmet needs are significant.

When to useWhen entering competitive markets, or within capital-constrained environments, where broad product development is financially infeasible or unlikely to yield competitive advantage. Ideal for biotech startups and companies targeting rare diseases.

Pharma-Biotech Partnership Model

A strategy for smaller biotech firms to leverage the resources, infrastructure, and market access of larger pharmaceutical companies through licensing agreements, co-development, or other collaborations.

When to useWhen a biotech requires significant capital infusion, clinical trial execution, or commercialization capabilities that it cannot independently fund or build, while retaining upside for its innovations.

Adjacent Minds